trials, stroke prevention trials, and stroke recovery trials has demonstrated early success in both improved rates of recruitment and patient diversity. Multiple network structures were described. International recruitment collaborations also have succeeded and are now feasible with advances in clinical electronics. In parallel with these advances in science and methodology, this session summarized progress in stroke prevention, treatment, and delivery of stroke treatment. Phase III clinical trials have been completed that have changed treatment guidelines. New drugs, new drug algorithms, and new devices have been developed to improve reperfusion. Stroke center-based innovations in care have been widely adopted and benefits are well-documented.
Future recommendations of the Stroke Progress Review Group will likely address the need for more science. Important areas include ischemic and hemorrhagic injury, aging and pathophysiology of blood vessels, clot formation and dissolution, and mechanism-based drug targets and drug candidates. For clinical stroke research, the new networking and other methods show promise. More work is needed, as is funding for models to sustain existing investigator teams and to attract and develop the investigators of the future.
